HORMONE EXAMINATION IN MENOPAUSE

ferdy royland marpaung, Trieva Verawaty Butarbutar, Sidarti Soehita

Abstract


World Health Organization (WHO) and Stages of Reproductive Aging Workshop (STRAW) define menopause as a permanent end point of menstrual cycle that occurs naturally or by induction of surgical procedure, chemotherapy, or radiation. Clinically, menopause involved women over 40 or 50 years old. Approximately, fifty million women in the world is experiencing menopause annually. The etiology of menopause is classified into physiologic and non-physiologic. Pathophysiology of menopause includes decline of ovary function in menopause, response to loss of ovarian feedback mechanism, decline of hypothalamus and pituitary function. Endocrine changes in menopause lead to alteration of gonadotropin secretion cycle patterns, changes in steroid and peptide hormones through monophasic patterns to increase gonadotropin, decrease of estrogen, progesterone and inhibin. Clinical symptoms of menopause or estrogen deficiency syndrome classified into short term clinical symptoms and long term clinical symptoms. Hormonal examination in menopause consist of Follicular Stimulating Hormone (FSH), Anti-Mullerian Hormone (AMH), Luteinizing Hormone (LH), Inhibin B and Estradiol. The important of time to examine the hormones should be considered carefully.


Keywords


menopause, follicular stimulating hormone, anti-mullerian hormone, luteinizing hormone, inhibin B, estradiol.

Full Text:

PDF

References


Edwards BJ, Li J. Endocrinology of menopause. Periodontol 2000. 2013;61(1):177–94.

Su HI, Freeman EW. Hormone changes associated with the menopausal transition. Minerva Ginecol. 2009;61(6):483–9.

DK E. Dewhurst’s Textbook of Obstetrics and Gynaecology. 7th Editio. 2007. 47; 479-493.

L B-PPP. Premature Ovarian Failure. Orphanet J Rare Dis. 2006;1:9.

Holt IG Richard HNA. Essential Endocrinology and Diabetes. 6th ed. London: Willey Blackweel; 2012. 127-164 p.

E HJ. Endocrinology of the Menopause. Endocrinol Metab Clin N Am 44. 2015;485–496.

Burger HG. Physiology and endocrinology of the menopause. Medicine (Baltimore). 2006;34(1):27–30.

O’Neill S, Eden J. The pathophysiology of menopausal symptoms. Obstet Gynaecol Reprod Med. 2017;27(10):303–10.

Jerilynn C Prior, Christine L Hitchcock.. The endocrinology of perimenopause: need for a paradigm shift Front Biosci. 2011;474–86.

Buckler H. The menopause transition: Endocrine changes and clinical symptoms. J Br Menopause Soc. 2005;11(2):61–5.

RF C. Clinical Manifestations and diagnosis of menopause. UpToDate [Internet]. 2018; Available from: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-menopause/print

Al PG et. Therapeutic Management of the Menopausal Transition. Front Gynecol Endocrinol ISGE Ser. 2014;

Release P, Set D, This I, Lbxfsh A, Sas L, Follicle L, et al. Follicle Stimulating Hormone ( FSH ) in Serum – NHANES 2001-2002 Follicle Stimulating Hormone ( FSH ) in Serum – NHANES 2001-2002. 2002;1–9.

Grynnerup AGA, Lindhard A, Sørensen S. The role of anti-Müllerian hormone in female fertility and infertility - An overview. Acta Obstet Gynecol Scand. 2012;91(11):1252–60.

NHANES. Luteinizing Hormone (LH) in Refrigerated Serum. Collab Lab Serv LLC. Available from: https://www.cdc.gov/nchs/data/nhanes/nhanes_01_02/l40_b_met_luteinizing_hormone.pdf.

Asihara Y and KY. Immunoassay and immunochemistry. 21th ed. Philadelphia: In:Jhon,BH (eds),Clinical Diagnosis and Management by Laboratory Methods. WB Saunders Company; 2001. 869-870 p p.

Linde R and GJ. Reproduction. Boston Butterworth-Heineman. James PG Lawrence VB (eds), Immunoass Lab Anal Clin Appl. 1994;400–416 p.

Richter MM. Electrochemiluminescence ( ECL ). 2004;(3).




DOI: http://dx.doi.org/10.24293/ijcpml.v25i2.1449

Refbacks

  • There are currently no refbacks.